Skip to content
Disclosery

GILEAD SCIENCES, INC.

Follow

13F filer, CIK 882095, FOSTER CITY, CA

GILEAD SCIENCES, INC. reported $1,648,747,919 across 5 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-03.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-26-001034

Period
2026-06-30
Reported value
$1.65B
Holdings
5
Top 10 weight
100%
New
0
Sold out
1

Part of the filer group GILEAD SCIENCES, INC.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ASMBadded+471,698$13M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ACLXexited-6,720,803-$772M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001123292-26-001034, largest first. % of portfolio is the value over $1,648,747,919, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not loaded; 2026Q1: 31,424,760 shares; 2026Q2: 31,424,760 shares 31,424,760$969M58.76%0Timeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not loaded; 2026Q1: 16,707,477 shares; 2026Q2: 16,707,477 shares 16,707,477$500M30.34%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not loaded; 2026Q1: 4,505,391 shares; 2026Q2: 4,977,089 shares 4,977,089$137M8.3%+471,698Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not loaded; 2026Q1: 4,126,119 shares; 2026Q2: 4,126,119 shares 4,126,119$36.8M2.23%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not loaded; 2026Q1: 650,389 shares; 2026Q2: 650,389 shares 650,389$6.23M0.38%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ACLXARCELLX INC6,720,803$772Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-26-001034 base2026-08-03acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001123292-26-001034 Quarter ended 2026-06-302026-08-03acceptance time not in the bulk data set
13F-HR 0001123292-26-000642 Quarter ended 2026-03-312026-05-08acceptance time not in the bulk data set
13F-HR 0001123292-26-000164 Quarter ended 2025-12-312026-02-12acceptance time not in the bulk data set
13F-HR 0001123292-25-000642 Quarter ended 2025-09-302025-11-13acceptance time not in the bulk data set